NCT06931561 Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
| NCT ID | NCT06931561 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inova Health Care Services |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-02-11 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-02-11 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to further understand the clinical impact and follow-up steps that may be required based on using whole-body Magnetic Resonance Imaging (MRI) or whole-body ultrasound and blood tests to detect multiple cancers in firefighters. This study involves an investigational test (cancer blood test) that has not been approved by the U.S. Food and Drug Administration (FDA). Whole-body MRI and whole-body ultrasound are approved by the U.S. Food and Drug Administration (FDA) to be used in the diagnosis of some cancers and is approved for adults and children who present other signs of potential disease. In this study, however, the whole-body MRI and the whole-body ultrasound are considered investigational devices because they are not yet approved for use in healthy adults with no other cancer indications.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 35 years old * at least 10 cumulative years working as a firefighter * Actively serving as a firefighter (active or volunteer) with completion of NFPA physical examination within the past 6 months * Ability to understand and willing to sign informed consent * Ability to understand and willing to sign the Health Insurance Portability and Accountability Act (HIPAA) Authorization * Additional eligibility criteria in protocol Exclusion Criteria: * No prior history of any invasive cancer within the previous 5 years (non-melanoma skin cancer and in situ carcinoma would still be eligible) and no current diagnostic workup for suspicion of cancer * Received a whole-body MRI, whole-body ultrasound, or been tested with a MCD within the past 1-year * For women of childbearing potential, pregnancy and no plans for pregnancy for the duration of the study * Additional exclusion criteria in protocol
Contact & Investigator
Stephanie Van Bebber
STUDY DIRECTOR
Inova Health System - Inova Schar Cancer
Frequently Asked Questions
Who can join the NCT06931561 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 85 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06931561 currently recruiting?
Yes, NCT06931561 is actively recruiting participants. Contact the research team at salman.baig@inova.org for enrollment information.
Where is the NCT06931561 trial being conducted?
This trial is being conducted at Fairfax, United States.
Who is sponsoring the NCT06931561 clinical trial?
NCT06931561 is sponsored by Inova Health Care Services. The principal investigator is Stephanie Van Bebber at Inova Health System - Inova Schar Cancer. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.